U.S. Markets closed

Has Curis (CRIS) Outpaced Other Medical Stocks This Year?

Zacks Equity Research

Investors focused on the Medical space have likely heard of Curis (CRIS), but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of CRIS and the rest of the Medical group's stocks.

Curis is one of 839 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CRIS is currently sporting a Zacks Rank of #2 (Buy).

Over the past 90 days, the Zacks Consensus Estimate for CRIS's full-year earnings has moved 44.94% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.

Based on the most recent data, CRIS has returned 63.82% so far this year. At the same time, Medical stocks have gained an average of 2.64%. This means that Curis is performing better than its sector in terms of year-to-date returns.

Breaking things down more, CRIS is a member of the Medical - Biomedical and Genetics industry, which includes 345 individual companies and currently sits at #58 in the Zacks Industry Rank. This group has gained an average of 8.89% so far this year, so CRIS is performing better in this area.

Investors with an interest in Medical stocks should continue to track CRIS. The stock will be looking to continue its solid performance.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Curis, Inc. (CRIS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research